Evaluation of Thyroid Functions in Patients with Multiple Sclerosis Before and after Treatment with Interferon Beta

Mohammed, Magda Shokry; Shoeib, Nihad Shoukry; Sabry, Inas Mohammed; Gawad, Dina Mohammed Abd El; Bahaaeldin, Ahmed Mohamed; Adly, Nermien Naim

doi:10.4172/2167-7948.1000227

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regardless of the calculation used, thyroid events are common in alemtuzumab-treated patients, whereas the rate is increased, although lower, in IFNbeta-1a-treated patients. 23 This may reflect the underlying predisposition to thyroid disease in RMS patients in general, 24 which can develop with therapies that modulate the immune system, and to differing extents based on their individual mechanisms of action. IFNbeta is thought to impact the thyroid through a direct inhibitory effect on iodine organification.…”

Section: Discussionmentioning

confidence: 99%

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

Dayan

Lecumberri

Muller

et al. 2023

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

Background Alemtuzumab is an effective therapy for relapsing multiple sclerosis. Autoimmune thyroid events are a common adverse event. Objective Describe endocrine and multiple sclerosis outcomes over 6 years for alemtuzumab-treated relapsing multiple sclerosis patients in the phase 3 CARE-MS I, II, and extension studies who experienced adverse thyroid events. Methods Endocrine and multiple sclerosis outcomes were evaluated over 6 years. Thyroid event cases, excluding those pre-existing or occurring after Year 6, were adjudicated retrospectively by expert endocrinologists independently of the sponsor and investigators. Results Thyroid events were reported for 378/811 (46.6%) alemtuzumab-treated patients. Following adjudication, endocrinologists reached consensus on 286 cases (75.7%). Of these, 39.5% were adjudicated to Graves’ disease, 2.5% Hashimoto's disease switching to hyperthyroidism, 15.4% Hashimoto's disease, 4.9% Graves’ disease switching to hypothyroidism, 10.1% transient thyroiditis, and 27.6% with uncertain diagnosis; inclusion of anti-thyroid antibody status reduced the number of uncertain diagnoses. Multiple sclerosis outcomes of those with and without thyroid events were similar. Conclusion Adjudicated thyroid events occurring over 6 years for alemtuzumab-treated relapsing multiple sclerosis patients were primarily autoimmune. Thyroid events were considered manageable and did not affect disease course. Thyroid autoimmunity is a common but manageable adverse event in alemtuzumab-treated relapsing multiple sclerosis patients. ClinicalTrials.gov Registration Numbers: CARE-MS I (NCT00530348); CARE-MS II (NCT00548405); CARE-MS Extension (NCT00930553)

show abstract

Section: Discussionmentioning

confidence: 99%

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

Dayan

Lecumberri

Muller

et al. 2023

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

show abstract

Prospective study of thyroid functions in multiple sclerosis patients treated with interferon beta in Alexandria University MS clinic

Talaat

Eldeeb

2021

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background The incidence of thyroid dysfunction in multiple sclerosis (MS) patients on interferon (as a disease-modifying line) has been reported in many studies performed on patients already on interferon therapy. Our study adopted a prospective follow-up of the thyroid profile in those patients newly starting interferon beta therapy over 1 year trying to find a correlation between the start of therapy and the occurrence of this dysfunction. Objectives To evaluate the incidence of thyroid dysfunction in MS patients before and 1 year after of interferon beta. Methods A prospective cohort study on 48 MS patients newly receiving interferon beta therapy through MS clinic were subjected to assessment of thyroid profile including serum TSH, free T3, and T4 at the start of treatment; they were followed-up at 6- and 12-month intervals after the start of therapy. Results and conclusion There was a statistically significant increase in serum-free T3 levels in those treated with interferon beta therapy in a follow-up of 1 year. Our work also showed a decrease in serum-free T4 levels without statistical significance. TSH levels showed a tendency towards increase without statistical significance.

show abstract

Evaluation of Thyroid Functions in Patients with Multiple Sclerosis Before and after Treatment with Interferon Beta

Cited by 2 publications

References 26 publications

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

Prospective study of thyroid functions in multiple sclerosis patients treated with interferon beta in Alexandria University MS clinic

Contact Info

Product

Resources

About